Moreover, the 36-month beta value for VIGL is 1.93. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VIGL is 14.91M and currently, short sellers hold a 6.18% of that float. On May 09, 2024, VIGL’s average trading volume was 85.83K shares.
VIGL) stock’s latest price update
The stock of Vigil Neuroscience Inc (NASDAQ: VIGL) has increased by 18.50 when compared to last closing price of 3.19. Despite this, the company has experienced a 42.64% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-05-08 that WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.
VIGL’s Market Performance
Vigil Neuroscience Inc (VIGL) has experienced a 42.64% rise in stock performance for the past week, with a 14.20% rise in the past month, and a 32.63% rise in the past quarter. The volatility ratio for the week is 14.06%, and the volatility levels for the past 30 days are at 10.25% for VIGL. The simple moving average for the last 20 days is 31.18% for VIGL stock, with a simple moving average of -16.29% for the last 200 days.
Analysts’ Opinion of VIGL
Many brokerage firms have already submitted their reports for VIGL stocks, with Morgan Stanley repeating the rating for VIGL by listing it as a “Underweight.” The predicted price for VIGL in the upcoming period, according to Morgan Stanley is $4 based on the research report published on December 19, 2023 of the previous year 2023.
JMP Securities, on the other hand, stated in their research note that they expect to see VIGL reach a price target of $23. The rating they have provided for VIGL stocks is “Mkt Outperform” according to the report published on October 18th, 2023.
Mizuho gave a rating of “Buy” to VIGL, setting the target price at $15 in the report published on March 31st of the previous year.
VIGL Trading at 23.08% from the 50-Day Moving Average
After a stumble in the market that brought VIGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.98% of loss for the given period.
Volatility was left at 10.25%, however, over the last 30 days, the volatility rate increased by 14.06%, as shares surge +18.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.83% upper at present.
During the last 5 trading sessions, VIGL rose by +42.64%, which changed the moving average for the period of 200-days by -49.26% in comparison to the 20-day moving average, which settled at $2.91. In addition, Vigil Neuroscience Inc saw 11.83% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIGL starting from Magovcevic-Liebisch Ivana, who purchase 4,000 shares at the price of $3.75 back on Nov 20 ’23. After this action, Magovcevic-Liebisch Ivana now owns 207,687 shares of Vigil Neuroscience Inc, valued at $15,000 using the latest closing price.
Stock Fundamentals for VIGL
Current profitability levels for the company are sitting at:
- -46.28 for the present operating margin
- 0.64 for the gross margin
The net margin for Vigil Neuroscience Inc stands at -42.8. The total capital return value is set at -0.77. Equity return is now at value -60.18, with -52.16 for asset returns.
Based on Vigil Neuroscience Inc (VIGL), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -5.14. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -85.65.
Currently, EBITDA for the company is -88.47 million with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 53.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.38.
Conclusion
To wrap up, the performance of Vigil Neuroscience Inc (VIGL) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
